Drug intelligence / Profile preview

SYMPT-XO

Development stage: Unknown
Lead developer: Taiwan Specialty Pharma
Administration: Oral, Parenteral

Overview

SYMPT-XO is a specialized nutritional supplement developed by Taiwan Specialty Pharma (TSPC) for the dietary management of cancer patients. It is formulated as a medical food to provide caloric supplementation and essential nutrients to individuals experiencing weight loss, malnutrition, or increased metabolic demands due to malignancy or oncology treatments. The product is part of the Sympt-X brand family, which is recognized in Taiwan for high-purity L-glutamine formulations used to alleviate treatment-related side effects such as oral mucositis. SYMPT-XO is designed to support the nutritional status and overall recovery of cancer patients undergoing chemotherapy or radiotherapy.

Brand names: SYMPT-XO速養遼癌症配方
Other names: Sympt-X OncologySympt-X Cancer Formula

Beyond the preview

Go deeper on SYMPT-XO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYMPT-XO.

Explore the full profile